Legend Biotech Corporation (LEGN) has released an update.
Legend Biotech Corporation has announced the FDA approval of CARVYKTI® for second-line treatment of multiple myeloma, marking it as the first BCMA-targeted CAR-T cell therapy available for this stage of the disease. The therapy offers a new option for patients who have relapsed and are refractory to standard treatments, potentially transforming the treatment landscape. Increased production capabilities have been established to meet the demand for this innovative treatment.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
